3D Medicines Approved to Launch Anti-PD-L1 in China
November 26, 2021 at 09:16 AM EST
3D Medicines reported that China 's NMPA approved the launch of its anti-PD-L1 therapy, the first subcutaneously administered anti-PD-L1 approved anywhere in the world. Envafolimab, a novel single-domain antibody against PD-L1, is approved as a second line therapy for MSI-H/dMMR cancer in patients with advanced solid tumors. Alphamab Oncology originally discovered the drug, and 3D Medicines became its partner, with both companies responsible for clinical development. Tracon Pharma shares US rights to envafolimab with the two China biopharmas while Simcere will commercialize envafolimab in China . More details... Stock Symbols: (HK: 9966) (NSDQ: TCON) Share this with colleagues: // //